Lixte Biotechnology (LIXT) Financials

Lixte Biotechnology (NASDAQ: LIXT) continues to look like a pre-revenue biotech company with no operating revenue and persistent losses, but the balance sheet and cash position improved sharply in the latest quarter thanks to equity financing. Over the last several years, the company has remained in a cash-burning development stage, with operating expenses far exceeding any income and little evidence of commercialization.

For Q1 2026, the company reported zero revenue and a net loss of $2.0 million, compared with a net loss of $2.5 million in Q4 2025 and $0.8 million in Q2 2025. Operating expenses rose to $2.0 million in the quarter, driven mainly by $1.65 million in SG&A and $333 thousand in R&D. The loss was also large relative to its share count, with basic and diluted EPS of $(0.18).

Cash flow remained negative from operations, with operating cash outflow of $1.86 million in Q1 2026. Investing cash outflow was modest at $24.9 thousand, and financing activities were flat in the quarter, meaning the company used more cash than it brought in. That resulted in a net cash decrease of $1.86 million during the quarter.

The company’s liquidity picture is stronger than it was a year ago, largely because it raised capital in 2025. As of March 31, 2026, Lixte held $3.25 million in cash and equivalents, up from $1.38 million at March 31, 2025 and well above the $887 thousand reported at June 30, 2025. Current assets totaled $3.41 million versus $989.8 thousand in Q2 2025, helping support near-term operations.

That said, the company is still not self-funding. Over the past four quarters, operating losses have generally ranged from roughly $0.6 million to $2.5 million per quarter, and cash from operations has stayed negative each period. The latest quarter’s operating cash burn of $1.86 million suggests the current cash balance could be consumed quickly if spending remains elevated and no additional capital is raised.

Key takeaways for investors:

• Cash and equivalents increased to $3.25 million at the end of Q1 2026, giving the company a better liquidity cushion than a year ago.
• Q1 2026 net loss improved versus Q4 2025, falling to $2.0 million from $2.5 million.
• Quarter-end current assets of $3.41 million exceeded current liabilities of $1.22 million.
• The company remains a pre-revenue biotech with no reported operating revenue across the periods provided.
• R&D spending in Q1 2026 was $333 thousand, showing the company is still investing in development, though not at a large scale.
• Non-controlling interest is meaningful on the balance sheet, which can make common equity interpretation more complex.
• Operating cash flow was negative $1.86 million in Q1 2026, indicating ongoing cash burn from core operations.
• The company reported no financing inflow in Q1 2026, so it did not replenish cash during the quarter.
• Accumulated deficit remains very large, with retained earnings of negative $60.0 million as of March 31, 2026.
• Lixte’s future likely depends on additional capital raises or a meaningful clinical/strategic milestone before cash is depleted.

Bottom line: Lixte Biotechnology’s latest quarter shows a company that is still burning cash and losing money, but with a noticeably improved cash balance versus earlier periods. For retail investors, the story remains highly speculative: the main positives are liquidity and a modest sequential improvement in losses, while the biggest risk is continued dilution or another financing round to keep the business running.